Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Business Wire
- Launched strategic clinical site partnerships to accelerate PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder (“MDD”) -- PARADIGM comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 patients -- APPROACH has been initiated and will enroll 220 participants at more than 40 clinical sites in the United States and Europe -- Upcoming milestones include topline efficacy data readout from CYB004 Phase 2 study in general anxiety disorder and initiation of EXTEND and EMBRACE pivotal studies of CYB003 around
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Cybin wins new Buy from Guggenheim: potential to challenge J&J's Spravato cited [Seeking Alpha]Seeking Alpha
- Cybin Inc. (NYSE: CYBN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.MarketBeat
- Podcast: How Trump's tariffs will impact clinical trials [Yahoo! Finance]Yahoo! Finance
- Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at HC Wainwright from $190.00 to $150.00. They now have a "buy" rating on the stock.MarketBeat
- Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $86.00 to $73.00. They now have a "buy" rating on the stock.MarketBeat
CYBN
Earnings
- 6/26/24 - Miss
CYBN
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/14/25 - Form 6-K
- 2/14/25 - Form SCHEDULE
- CYBN's page on the SEC website